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introduction
The polymorphic CGG trinucleotide repeat in the FMR1 gene is 
associated with three different phenotypes.1 Full mutations have 
over 200 CGG repeats and are usually fully methylated, causing 
inactivation of the gene. Loss-of-function mutations in FMR1 
give rise to fragile X syndrome, characterized by moderate-to-
severe learning difficulties and social deficits and more often 
affecting males than females. A premutation category of smaller 
repeats, with 55–200 CGGs, is associated with fragile X tremor 
and ataxia syndrome and primary ovarian insufficiency (POI). 
Fragile X tremor and ataxia syndrome is a late-onset progressive 
neurological disorder that affects mainly males.2 POI is defined 
as permanent cessation of menstruation occurring naturally 
before the age of 40 years.3 POI affects ~1% of the general female 
population but has been reported in ~24% of premutation car-
riers in fragile X families.4,5 Women carrying premutation-sized 
repeats go through menopause ~5 years earlier than noncarriers 
in their families.6 Although the exact molecular mechanism by 
which FMR1 premutations affect phenotype is unknown, there 
is substantial evidence for an RNA gain-of-function effect, as 
only premutation and not full-mutation carriers are at risk for 
fragile X tremor and ataxia syndrome and POI, and RNA levels 
are increased in premutation carriers, whereas no RNA is pro-
duced from methylated full-mutation alleles.5,7
Several studies have investigated the prevalence of the FMR1 
premutation in series of women ascertained via POI. Other 
genetic causes of POI have been reported, including X chro-
mosome abnormalities and mutations in genes such as FOXL2 
and FSHR. These represent <5% of cases, but in the majority of 
cases the cause is unknown.8 FMR1 premutations are thought 
to account for ~5% of all POI cases and more if it is a familial 
condition.6,9,10 Several recent reports have also suggested that 
smaller repeats in the higher end of the normal range (inter-
mediate or gray-zone alleles) also affect ovarian function.11–13 
However, all previous studies on the incidence of premutation 
and intermediate alleles in POI have been in women who were 
having clinical investigations either for POI or infertility. These 
cases are selected and hence could have increased prior odds 
of finding a premutation, perhaps because of an undisclosed 
family history. Therefore, in the absence of a population-based 
Purpose: Primary ovarian insufficiency before the age of 40 years 
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but these are likely to be biased as compared with cases in the gen-
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Methods: We studied FMR1 CGG repeat number in more than 
2,000 women from the Breakthrough Generations Study who under-
went menopause before the age of 46 years. We determined the 
prevalence of premutation (55–200 CGG repeats) and intermediate 
(45–54 CGG repeats) alleles in women with primary ovarian insuf-
ficiency (n = 254) and early menopause (n = 1,881).
results: The prevalence of the premutation was 2.0% in primary 
ovarian insufficiency, 0.7% in early menopause, and 0.4% in con-
trols, corresponding to odds ratios of 5.4 (95% confidence interval 
= 1.7–17.4; P = 0.004) for primary ovarian insufficiency and 2.0 
(95% confidence interval = 0.8–5.1; P = 0.12) for early menopause. 
Combining primary ovarian insufficiency and early menopause gave 
an odds ratio of 2.4 (95% confidence interval = 1.02–5.8; P = 0.04). 
Intermediate alleles were not significant risk factors for either early 
menopause or primary ovarian insufficiency.
conclusion: FMR1 premutations are not as prevalent in women with 
ovarian insufficiency as previous estimates have suggested, but they 
still represent a substantial cause of primary ovarian insufficiency 
and early menopause.
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estimate, it is difficult to assess the impact of this mutation on 
reproductive life span. Moreover, the majority of previous stud-
ies have solely investigated women with POI, which has been 
fairly arbitrarily defined on the basis of the population distri-
bution of menopause. We do not know whether women with 
early menopause (EM) after 40 years of age are also at signifi-
cant risk of carrying a premutation. We therefore tested a series 
of women with menopause at or before 45 years of age from 
the population-based Breakthrough Generations Study (BGS) 
to determine the prevalence of FMR1 CGG repeat expansion 
mutations, both in those having POI and in those having EM.
MAteriALs And MetHods
study population
The BGS is a UK prospective epidemiological cohort study 
that started recruitment in 2003. The primary objective of the 
BGS is to investigate the environmental, behavioral, hormonal, 
and genetic causes of breast cancer and also investigate the 
causes of other cancers and diseases.14 The cohort consists of 
more than 110,000 women from the general population of the 
United Kingdom aged 16 years and older at the date of entry. 
Recruitment is through volunteers connected with the charity 
Breakthrough Breast Cancer, volunteers responding to pub-
licity, and their friends, family members, and other contacts. 
Each participant completes a questionnaire, and most pro-
vide a blood sample for the analysis of genomic, hormonal, 
and other blood factors. Participants are questioned on their 
detailed menstrual histories, thus enabling the identification 
of the subjects in the current analyses. Natural menopause was 
defined as the cessation of menstruation for at least 6 months 
without known cause. Women were excluded if their periods 
stopped because of pregnancy, breastfeeding, surgery, hor-
monal contraceptive use, or other types of medical treatment, 
or if there was a medical condition or illness that could have 
caused amenorrhea (e.g., polycystic ovary syndrome). We also 
excluded women with a history of breast cancer as cases and 
controls. EM cases were women who had natural menopause 
between 40 and 45 years of age and POI cases had menopause 
before 40 years of age. We selected one control for each EM and 
POI case, at random within matching criteria of date of birth 
(within 12 months if possible), ethnicity, year of questionnaire 
completion, and source of recruitment. Overall, there were 126 
cases who were younger than 46 years at entry to the study, 
and controls aged 46 years at entry to the study were selected 
for each of these cases. Women were eligible to be enrolled as 
controls if they were postmenopausal at entry to the study with 
a menopausal age of 46 years or older (74.3%) or if they were 
premenopausal and entered the study at the age of 46 years or 
older (25.7%). Menopause at the age of 46 years or older could 
be natural or surgically induced, provided there was evidence 
that the women were still menstruating after the age of 45 years. 
When multiple individuals from one pedigree were available, 
we included only the youngest individual who met the above 
criteria. We successfully genotyped 2,135 women with natural 
menopause before the age of 46 years and 1,915 controls with 
menopause after the age of 45 years; details are given in Table 1.
Genotyping
For each subject, Asuragen Amplidex kits (http://www. 
asuragen.com/) containing FMR1 CGG repeat region–specific 
primers were used to PCR amplify the FMR1 repeat region from 
20 ng of genomic DNA that had been extracted from peripheral 
blood mononuclear cells. All PCRs were performed in 3 µl of 
reaction volumes in 384-well microtiter plates, using condi-
tions recommended by the kit manufacturers. Products were 
size separated by capillary electrophoresis on an ABI 3730 auto-
mated sequencer (Applied Biosystems, Warrington, UK), using 
ROX 1000 size standard (Asuragen, Austin, TX, USA) for esti-
mation of product sizes. CGG repeat numbers were determined 
by comparison with a control individual of 52 CGG repeats. 
We included duplicates of 776 of the samples (20%) on inde-
pendent plates. The concordance between duplicate samples 
was 98.5%, excluding differences of ±1 CGG repeat. Controls 
included 12 no-template controls, 3 samples from females of 
known expansion size (largest CGG = 55, 117, and 145), and a 
lane containing the multiple size targets supplied by Asuragen 
(CGG = 20, 29, 31, 53, 117, and 196) per 384 plate.
Analysis methods and models
The association between CGG repeat length and age at natu-
ral menopause was tested by logistic and linear regression 
analysis in STATAv12 (http://www.stata.com). Models testing 
table 1 Summary statistics for individuals included in the analysis
controls Poi eM eM+Poi
Number of participants 1,915 254 1,881    2,135
Premutation (55–200 CGG repeats) (n, %) 7 (0.4) 5 (2.0) 14 (0.7) 19 (0.9)
Intermediate (45–54 CGG repeats) (n, %) 53 (2.8) 7 (2.8) 56 (3.0) 63 (3.0)
Alleles <45 CGG repeats (n, %) 1,855 (96.9) 242 (95.3) 1,811 (96.3) 2,053 (96.2)
Age at recruitment (mean, SD) 58.7 (8.6) 53.9 (10.1) 60.0 (8.4) 58.4 (8.4)
Age at menopause (mean, SD) 51.8 (2.7) 36.0 (4.1) 43.2 (1.6) 42.5 (3.2)
Percentage of ever cigarette smokers 35.7 41.3 41.0 41.0
Percentage of European descent 99.43 98.82 99.57 99.48
EM, early menopause; POI, primary ovarian insufficiency.
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the CGG repeat as continuous and categorical variables were 
investigated against age at menopause as both continuous 
and categorical variables. We tested the effect of the longest 
CGG repeat allele on EM and POI, both with and without the 
smaller allele as a continuous variable covariate, the hypoth-
eses being that expansions may act as dominant alleles or may 
act additively with the second, smaller repeat. The largest CGG 
repeat was categorized as premutation (55–200 CGG repeats) 
or intermediate (45–54 CGG repeats) based on accepted defi-
nitions (http://www.acog.org/), although these definitions are 
largely based on the thresholds that determine instability of the 
repeat and may not be as relevant for determining thresholds 
for phenotypic effects. For analysis, risk in relation to premuta-
tions was compared with subjects with <55 CGG repeats (i.e., 
including the intermediate category), and risk in relation to 
intermediate repeats (45–54) was compared with subjects with 
<45 CGG repeats.
Age at natural menopause was analyzed in two different ways:
1. As a quantitative trait using age at last menstrual period, in 
both a linear and quadratic model.
2. As a case–control outcome, with EM (40–46 years of age) 
as the cases, and then with POI (menopause before 40 
years of age) as the cases. In both instances, women with 
menopause after 45 years constituted the control group. 
We also tested the frequency of CGG repeat expansions in 
EM and POI cases combined.
resuLts
Prevalence of FMR1 expansion alleles in women with eM 
and Poi
There was a significant excess of FMR1 premutation-sized 
repeats in women with POI, with 2% having premutation-sized 
repeats as compared with 0.4% of controls (Table 1) (P = 0.008 
by Fisher’s exact test). In 0.7% of women with EM, we detected 
a FMR1 premutation (P = 0.13 by Fisher’s exact test). Women 
with POI had more than a fivefold increased odds of being 
premutation carriers (odds ratio (OR) = 5.4; 95% confidence 
interval (CI) = 1.7–17.4; P = 0.004), whereas women in the 
EM group were at twofold increased odds (OR = 2.0; 95% CI = 
0.8–5.1; P = 0.12). When women with EM and POI were com-
bined, i.e., for women with menopause occurring at <46 years, 
the odds of being a premutation carrier was >2 (OR = 2.4; 95% 
CI = 1.02–5.8; P = 0.04). Intermediate alleles were not signifi-
cantly associated with either EM or POI (Table 2). The ORs 
were not substantially affected by including the smaller CGG 
repeat allele as a covariate (Table 2). There was no evidence for 
a continuous per-repeat effect of CGG number on menopause 
age or case/control status (data not shown). There was no linear 
or curvilinear association between age of menopause and num-
ber of CGG repeats in the premutation range (P = 0.29 and P = 
0.28, respectively), but inclusion of intermediate alleles gave a 
better fit for the curvilinear model (P = 0.035).
Smoking is the most robustly associated environmental 
factor affecting menopause age,15 and the OR for being an 
EM or POI  case for individuals who had ever smoked was 
OR =  1.3  (95%  CI = 1.1–1.4; P = 0.0002). We investigated 
the potential impact of smoking status in a sensitivity analy-
sis, repeating the association tests in women who had never 
smoked and women who had ever smoked over their lifetime 
in separate analyses: no significant differences were observed 
(Supplementary Table S1 online). In an interaction analysis, a 
log likelihood ratio test found no evidence that the OR for POI 
or EM for premutation alleles was modified by smoking status 
(P = 0.29 and 0.71, respectively).
repeat sizes observed
The expanded premutation-sized alleles observed in con-
trols were all <66 repeats. The larger premutation alleles (>65 
repeats) were all in women with either EM or POI (Figure 1).
discussion
We found an excess of FMR1 premutation alleles in both women 
with EM and women with POI in our large sample of indi-
viduals. Although the BGS cohort consists of volunteers from, 
rather than random members of, the general population, they 
included substantial numbers from all sections of society and 
geographical areas of the UK, and it is highly unlikely that par-
ticipants volunteered on the basis of the combination of their 
menopausal status and FMR1 status (which would be unknown 
to them), so they probably give a close estimate of the associa-
tion in the population overall. A limitation of this study is that it 
relied on recalled menopause age. Recall of menopause age has 
been reported to be reliable in other studies,16 but recall errors 
could lead to misclassification when the data were grouped as 
POI, EM, or controls. If such misclassification occurred nondif-
ferentially, then it would be expected to reduce the ORs.
table 2 Odds ratio for EM or POI as compared with 
 controls for carriers of premutation and intermediate 
FMR1 alleles
Premutation alleles intermediate alleles
or (95% ci) P or (95% ci) P
POI vs. controls 5.47 (1.72–17.38) 0.004 1.01 (0.46–2.25) 0.98
POI vs. controls 
(small CGG 
repeat as 
covariate)
5.24 (1.64–16.69) 0.005 0.99 (0.45–2.21) 0.98
EM vs. controls 2.04 (0.82–5.08) 0.12 1.08 (0.74–1.58) 0.68
EM vs. controls 
(small CGG 
repeat as 
covariate)
2.01 (0.81–5.00) 0.13 1.05 (0.72–1.54) 0.80
EM + POI vs. 
controls
2.45 (1.03–5.83) 0.04 1.07 (0.74–1.56) 0.71
EM +POI vs. 
controls (small 
CGG repeat as 
covariate)
2.39 (1.00–5.70) 0.05 1.04 (0.72–1.51) 0.83
CI, confidence interval; EM, early menopause; OR, odds ratio; POI, primary 
ovarian insufficiency.
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Previous estimates of the frequency of premutation alleles in 
women ascertained through POI range from 0 to 10%, with a 
combined prevalence across published studies for 55–200 repeat 
alleles of ~4% (Supplementary Table S2 online). The preva-
lence is reported as being higher in individuals with a family 
history of POI, although most studies did not report data for 
familial and sporadic cases separately. To our knowledge, this 
is the first population-based study that examined individuals at 
the extreme end of the general population menopause age distri-
bution rather than clinical referrals for EM. We found a fivefold 
increased odds of having POI in female carriers of a premuta-
tion allele as compared with a 10-fold increased odds in our pre-
vious studies in an independent group of patients ascertained 
through clinical referral for POI, but the 95% CI in our current 
study includes an OR of 10.10,17 It is possible that clinical referrals 
are enriched for cases at the severe end of the menopause spec-
trum, or with a family history, and thus may be more likely to 
have a genetic etiology. Differences between studies may reflect 
true phenotypic differences in the women classified as POI. 
Some studies report families that included fragile X–affected 
males13,18,19 who were diagnosed before testing females with POI 
and thus it is difficult to be certain that the index POI case would 
have been ascertained independently; these cases may therefore 
increase the prior odds of finding a premutation.18 Alternatively, 
there may be a reporting bias, whereby studies with negative or 
borderline associations are less likely to be published. A pop-
ulation-based sample, unbiased with regard to menopause or 
fragile X status, should therefore give the best estimate of the 
prevalence of the expansion mutation.
This is the first study that has tested a large number of women 
with EM as well as those with POI. These women might not seek 
medical attention but represent 10% of the women recruited at 
ages of 60 years or more in our BGS population. The raised OR 
in premutation carriers in our study was not statistically sig-
nificant, but if confirmed in future studies, then a much larger 
number of individuals may be affected by premutations than 
would be the case if the association were limited to women with 
POI. For three of the women with EM in our data, the premuta-
tion allele was 100 repeats or greater, a size that in families iden-
tified through fragile X syndrome would almost always expand 
Figure 1 FMR1 cGG repeat sizes >45, for the largest allele, in women with Poi, eM, and menopause after 45 years of age (controls). EM, early 
menopause; POI, primary ovarian insufficiency.
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to a full mutation during a single maternal transmission. Other 
alleles were at the lower end of the premutation spectrum, with 
fewer than 60 CGG repeats. We were not able to follow up these 
alleles in family-based studies, but it is important to determine 
whether premutation alleles ascertained in this way, i.e., in the 
absence of a full mutation, are equally unstable. There is some 
evidence to suggest that these alleles may be more stable, but 
further studies are required.20 It is difficult to recommend test-
ing for these mutations routinely until the implications of find-
ing premutations in females with EM are fully understood. On 
the basis of prevalence alone, testing the FMR1 gene in women 
with EM would have as good a detection rate for the premuta-
tion as screening children with developmental delay/learning 
difficulties has for the full mutation; therefore, many new fami-
lies that segregate the mutation could be identified by testing 
women with EM. The counseling of families identified in this 
manner will be substantially different from the counseling of 
families with fragile X syndrome, and the uptake of family test-
ing is also likely to be different. In many cases, the reason for 
testing will not be to provide reproductive advice to the index 
case with EM, as she will generally not be able to conceive natu-
rally, but the diagnosis will have implications for the wider fam-
ily, for both reproductive health and the possibility of having 
offspring with fragile X syndrome. Although premutation-sized 
FMR1 repeats are substantial risk factors for EM and POI, pre-
mutations are also found in women with menopause occur-
ring after 50 years of age (Figure 2), and therefore, it is possible 
that additional causative mutations are present in EM and POI 
cases, and further diagnostic testing should not be disregarded.
Previous studies have reported an increased frequency of 
intermediate-sized FMR1 alleles in cases of POI and EM.12,13 
This would fit with a molecular model whereby a linear increase 
in RNA levels with increasing CGG repeat number has a linear 
effect on menopause age. Previous studies from our own lab21 
and the current study were not able to confirm an association 
between EM/POI and intermediate/large normal FMR1 alleles. 
Together, these studies were considerably larger than other 
published reports, but it is unclear how the study designs differ. 
It is possible that there are differences in specific populations 
tested, given that both of our studies were in UK-based cohorts, 
whereas other reports have come from Italy, Canada, and the 
United States, or again there might be positive reporting bias. 
The largest study implicating intermediate alleles in ovarian 
function came from an American group that tested 535 women 
with occult POI, i.e., who were still cycling but had raised folli-
cle-stimulating hormone or poor response to ovarian stimula-
tion.11 The prevalence of intermediate alleles was 3.2% in these 
women as compared with 1.3% in controls (P = 0.046). In the 
current study of 1,881 EM cases and 254 POI cases, no excess 
of intermediate alleles was seen, and there was no evidence for 
a quantitative, per-repeat, effect on menopause age. Our study 
was sufficiently powered to detect an association with inter-
mediate alleles, with >80% power to detect an OR of 1.5 for 
POI in intermediate carriers, whereas previous studies have 
reported ORs of 2.4–4.8.11–13 Therefore, although we cannot 
discount an association, we suggest the effect of intermediate 
alleles on ovarian function is at most weaker than previous 
studies would suggest. Two studies have reported a nonlinear 
effect of premutation size on menopause age, and therefore, a 
simple relationship between mRNA levels and menopause age 
may not explain the association with FMR1 expansions.22,23 In 
this study, we found no correlation between CGG number and 
menopause age within the premutation category, but we did not 
have many cases of large premutation carriers and were not as 
well powered as previous studies to detect an association. We 
did however find a borderline significant association with CGG 
repeat number >44 in the curvilinear model.
In summary, FMR1 premutations may not be as common 
a cause of ovarian failure as previous estimates suggest, but 
they still represent an important cause of ovarian failure and 
therefore give a reason to test women with POI and EM for the 
mutation.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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